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Background: There is limited data regarding the outcomes after stepwise ablation for persistent atrial
ﬁbrillation (AF) in patients with heart failure (HF).
Methods and results: Patients without structural heart disease undergoing stepwise ablation for
persistent AF (continuous AFr1 year) were studied (n¼108; age, 61710 years) and 32 patients had
a history of HF. The HF patients were further grouped on the basis of left ventricular ejection fraction
(LVEF)r45% (n¼15) and 445% (n¼17). During a median follow-up period of 2.2 years, repeated
ablations were necessary in 65 patients. The proportion of patients that were arrhythmia free 1 year
after the last ablation was 67% in patients with LVEFr45%, 86% in LVEF445%, and 91% in no HF
(p¼0.0009). In patients with LVEFr45%, the AF burden was reduced to less than one paroxysmal
episode per month, and patients with and without recurrences both showed signiﬁcant increases in
LVEF over the follow-up period (3877% to 60710% and 3776% to 53710%, respectively).
Conclusions: HF patients with LVEFr45% had lower chances to remain free from arrhythmias after stepwise
ablation for persistent AF than those with LVEF445%. Nevertheless, LVEF also improved in patients with
recurrences, reﬂecting the observed reduction in AF burden and emphasizing the beneﬁts of ablation.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) often exacerbates heart failure (HF) and HF
predisposes patients to the development and progression of AF [1,2].
This interplay between AF and HF signiﬁcantly increases hospitali-
zation and mortality. In patients with AF and HF, pharmacological
rhythm control therapy was not found to be superior to rate control
therapy [3], although it was reported that left ventricular (LV)
function improved after catheter ablation for AF [4,5]. Catheter
ablation for AF is therefore recommended for patients with HF [6].
However, some studies have shown that LV dysfunction is asso-
ciated with poor clinical outcome of catheter ablation for AF [7–9].
In the last decade, ablation techniques and technologies have
been developed for isolation of the pulmonary veins (PVs) [10,11]. In
particular, the efﬁcacy of PV isolation is limited for persistent AF. To
improve clinical outcomes, ablation techniques for atrial substratert Rhythm Society. Published by E
r Medicine, National Disaster
190-0014, Japan.
.jp (Y. Takahashi, MD).modiﬁcation were also developed [12–14]. Stepwise ablation, which
includes atrial substrate ablation in addition to PV isolation, is highly
effective in treating persistent AF [15]. It is unknown whether LV
dysfunction is a predictor of tachyarrhythmia recurrences, even with
the stepwise ablation strategy. Furthermore, little is known about
the association between tachyarrhythmia recurrence and changes in
LV function after ablation for AF in HF patients.
The ﬁrst aim of the present study was to assess arrhythmia-
free rate after stepwise ablation for persistent AF in HF patients in
comparison with patients without HF. The second aim was to
assess changes in LV ejection fraction (LVEF) in HF patients with
and without tachyarrhythmia recurrences over the course of the
follow-up period.2. Methods
2.1. Study population
Patients undergoing stepwise ablation for symptomatic and
persistent AF were eligible for this study. Persistent AF waslsevier B.V. All rights reserved.
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patients with a prior history of HF underwent echocardiography
and coronary angiography or coronary computed-tomography
angiography for the assessment of structural heart disease before
ablation. Exclusion criteria were New York Heart Association
(NYHA) functional class III or IV at the time of the ablation, prior
cardiac surgery, or structural heart disease, including prior
myocardial infarction, ischemic cardiomyopathy, valvular disease,
and hypertrophic cardiomyopathy. For the aims of this study,
patients who were diagnosed with dilated cardiomyopathy were
included because reduced LV dysfunction may be attributed to
AF [4]. In patients with a prior history of HF, LV function was
reassessed at least one month after conventional pharmacological
therapy for HF, including rate control drugs. Based on the LV
function reassessment results after one month of medical ther-
apy, the patients were grouped by LVEF values of r45% and
445%. Patients without a history of HF served as controls. All
patients provided informed written consent before undergoing
the ablation protocol.2.2. Electrophysiological study
All anti-arrhythmic drugs were discontinued at least 5 half-
lives prior to ablation. No patients were taking amiodarone.
Patients with a history of HF were treated with drugs, including
diuretics, angiotensin-converting enzyme inhibitors, or angioten-
sin receptor blockers, b-blockers, or digitalis, for at least one
month. Warfarin was administered for at least one month prior
to the procedure with a target international normalized ratio of
2.0–3.0 and was continued during the periprocedural period.
Transesophageal echocardiography was performed one day
before the procedure to conﬁrm the absence of atrial thrombi.
A multielectrode catheter was deployed in the coronary sinus
from the jugular vein. Two boluses of 50 IU/kg of heparin were
administered, one prior to transseptal puncture and the second
immediately after transseptal puncture. The activated clotting
time was evaluated at least every 30 min and maintained at
Z300 s during the procedure. The surface ECG and bipolar
intracardiac electrograms were monitored on a computer-based
digital ampliﬁer/recording system (Labsystem Pro, Bard Electro-
physiology, Lowell, MA). The intracardiac electrograms were
ﬁltered with a bandpass of 30–500 Hz and measured with online
calipers at a sweep speed of 100 mm/s.
2.3. Stepwise ablation for persistent AF
Ablation was performed using an irrigated-tip catheter (Navistar
Thermocool, Biosense-Webster, Diamond Bar, CA) under the
guidance of a 3D mapping system (CARTO, Biosense-Webster).
Contrast-enhanced computerized tomography (CT) of the left
atrium (LA) and PVs was performed before ablation and the CT
image was integrated with a 3D navigation system during the
procedure. Radiofrequency (RF) energy was delivered up to 35 W
for the mitral isthmus line and cavotricuspid isthmus, and 30 W
for other regions, respectively.
Catheter ablation was performed during ongoing AF as
described previously [15,16]. The goal of the procedure was
termination of AF (conversion to atrial tachycardia [AT] or
restoration of sinus rhythm) by ablation. First, PV isolation was
performed, guided by a circumferential decapolar electrode
catheter. If isolation of all PVs failed to terminate AF, electro-
gram-based ablation in the LA or coronary sinus was performed.
Characteristics of local electrograms targeted in the LA or cor-
onary sinus were as follows: [1] continuous activity, [2] centrifu-
gal activation pattern, [3] short cycle length activity (Z10 msshorter than that in the surrounding area), and [4] activation
gradient [17]. If AF continued after elimination of the electro-
grams with the characteristics mentioned above in all areas in the
LA and coronary sinus, LA linear ablation at the roof and mitral
isthmus were performed. If LA linear ablation failed to terminate
AF, the sinus rhythm was restored by electrical cardioversion. No
anti-arrhythmic drugs were administered to the patients during
the procedure.
After restoration of the sinus rhythm, cavotricuspid isthmus
linear ablation was performed in all patients. Regardless of
whether AF was terminated by ablation or not, isolation of all
PVs and conduction block of all linear lesions were validated
during sinus rhythm or atrial pacing, as appropriate. If residual
conduction gaps were identiﬁed, ablation was continued to
achieve isolation of the PVs and conduction block of the line.
For validation of conduction block of the roof line, a pacing
catheter and the ablation catheter were deployed at the LA
appendage and LA roof, respectively. For validation of mitral
isthmus line block, a multielectrode catheter in the coronary
sinus and ablation catheter in the LA were used for pacing and
mapping.
During RF delivery in the posterior wall of the LA, esophageal
temperature was monitored using a temperature probe. RF was
discontinued when the esophageal temperature reached 41 1C
[18]. Additional RF was not delivered at the same site until the
esophageal temperature decreased to 39 1C.2.4. Follow-up
Following the ablation, 100 mg of ﬂecainide was administered
for 2 months unless the patient had HF or sinus bradycardia. After
this period, all anti-arrhythmic drugs were discontinued. Discov-
ery of persistent or paroxysmal episodes of continuous AF/AT
for 430 s after the 2-month blanking period was regarded as a
recurrence of tachyarrhythmia. If required, a repeat procedure
was performed after the blanking period.
The patient was monitored 2, 4, and 6 months after the
procedure, and then at least every 6 months in our outpatient
clinic. Electrocardiographic (ECG) recording was conducted dur-
ing each follow-up, and 24-h Holter monitoring was performed at
4 and 6 months after the procedure, and every 6 months there-
after. Symptomatic patients were provided with a portable ECG
monitor (Omron, Kyoto, Japan) for event monitoring in the study
duration.2.5. Statistical analysis
The data are presented as the mean7standard deviation for
normally distributed variables and as median and interquartile
range for non-normally distributed variables. Continuous vari-
ables grouped by LVEF or HF were compared using one-way
analysis of variance (ANOVA) or Kruskal–Wallis test, as appro-
priate. Comparison of proportions was performed by Fisher’s
exact test. Comparison of LVEF from before and one year
after the ablation was performed using paired Student’s t test.
Freedom from tachyarrhythmias was analyzed using Kaplan–
Meier method. A log-rank test was used to compare estimates
of the arrhythmia-free rate across groups. Multivariable predic-
tors were identiﬁed using Cox proportional hazard regression
methods. Relative risks were expressed as a hazard ratio with
95% conﬁdence interval. A p value less than 0.05 was considered
to be statistically signiﬁcant. All statistical analyses were per-
formed using Statistical Package for the Social Sciences (SPSS,
version 15.0).
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Among 125 consecutive patients undergoing stepwise ablation
for persistent AF, 17 patients (14%) were excluded because of
prior cardiac surgery or structural heart disease (6 patients with
prior myocardial infarction; 4, prior cardiac surgery; 4, hyper-
trophic cardiomyopathy; and 3, mitral valvular disease). Of the
108 patients studied, 15 (14%) had a history of HF and LVEFr45%,
17 (16%) had a history of HF and LVEF445%, and 76 (70%) had no
history of HF.
Baseline characteristics of the 108 patients are shown in
Table 1. Regardless of LVEF, patients with a history of HF had
shorter AF and continuous AF durations and higher CHADS2
scores, and LA diameter than those in patients without a history
of HF. All patients with history of HF and LVEF445% showed
improvement in NYHA functional class after rate control therapy;
therefore, they were diagnosed as tachycardia-induced cardio-
myopathy by the physicians who referred them.3.1. The index procedure outcome
Baseline LA cycle length, deﬁned as the average of 30 con-
secutive AF cycles at the LA appendage, was compared across theTable 1
Baseline characteristics.
Total (n¼108) HF and LVEFr45% (n
Age (years) 61710 61710
Male (%) 77 73
AF duration (months) 10 (4–60) 4 (3–10.5)
Continuous AF duration (months) 4 (2–7) 3 (3–5)
Hypertension (%) 41 27
Diabetes (%) 11 20
History of stroke (%) 8 13
CHADS2 score 1 (0–2) 1 (1–3)
Left atrial diameter (mm) 4274 4574
LVEF (%) 59711 3977
LV diastolic diameter (mm) 4976 5676
BNP (pg/mL) 137 (74–210) 237 (86–358)
Prior cardioversion (%) 19 33
Values are given as the mean7standard deviation (SD) or as the median with interqu
Fig. 1. Left atrial cycle length before ablation (A) and proportion of patients whose AF te
ventricular ejection fraction. Whiskers represent standard deviation of the mean.3 groups (Fig. 1A). Patients with HF and LVEF445% had the
highest LA cycle length (p¼0.0001).
In 47 patients (44%), AF was terminated by ablation during the
index procedure. The AF termination rate of each group is shown
in Fig. 1B. The rate of AF termination was highest in patients with
HF and LVEF445%, although it did not reach statistical signiﬁ-
cance (p¼0.057). This trend was analogous to the LA cycle length
of these 3 groups. Of these 47 patients, PV isolation terminated AF
in only 7 patients (15%). In the remaining 40 patients (85%),
electrogram-based ablation, in combination with PV isolation,
terminated AF in 14 patients (30%), and further linear ablation
terminated AF in 26 patients (55%). Fig. 2 shows the ablation
techniques performed in each group. PV isolation alone did not
terminate AF in any patient with HF and LVEFr45%. Procedural
and RF duration and irrigation volume were similar across the
3 groups (Table 2).
Complications occurred in 2 patients (2%) during the peripro-
cedural period. One patient without HF had a transient ischemic
stroke 2 day after the ablation. The other patient with HF and
LVEFr45% had gastric hypomotility, which spontaneously resolved
in 5 day. No patient showed worsening of HF during the peripro-
cedural period.
The median follow-up period from the index procedure
was 2.2 years (interquartile range: 0.9–3.3 years). From the¼15) HF and LVEF445% (n¼17) No HF (n¼76) p value
6478 61710 0.5
65 80 0.3
7.5 (3–54) 12 (5.5–60) 0.04
2 (1.5–4.5) 4 (3–8) 0.02
41 43 0.5
12 9 0.4
18 5 0.1
2 (1–2) 0.5 (0–1) o0.0001
4475 4174 0.001
5877 6377 o0.0001
4975 4775 o0.0001
191 (140–315) 109 (70–180) o0.0001
18 16 0.3
artile range in parentheses.
rminated (B) during the index ablation in each group. HF¼heart failure; LVEF¼ left
Fig. 2. Ablation techniques used in each group. PVI¼pulmonary vein isolation;
egm-based ABL¼electrogram-based ablation; linear ABL¼ linear ablation.
Table 2
Procedural and radiofrequency duration and irrigation volume in the index
procedure.
HF and LVEF
r45% (n¼15)
HF and LVEF
445% (n¼17)
No HF
(n¼76)
p
value
Procedural
duration (min)
224735 208751 224745 0.4
RF duration
(min)
80716 84729 84723 0.8
Irrigation
volume (L)
1.9970.31 1.8670.54 1.8570.54 0.5
Values are given as the mean7standard deviation (SD).
Fig. 3. Freedom from tachyarrhythmia after the index ablation procedure.
Comparison of patients with heart failure (HF) and left ventricular ejection
fraction (LVEF)r45%, those with HF and LVEF445%, and those without HF.
Fig. 4. Freedom from tachyarrhythmia after the last ablation. Comparison of
patients with heart failure (HF) and left ventricular ejection fraction (LVEF)r45%,
those with HF and LVEF445%, and those without HF.
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up were estimated to be 36% in patients with HF and LVEFr45%,
27% in patients with HF and LVEF445%, and 40% in patients with
no HF (log-rank test, p¼0.12; Fig. 3).
3.2. Repeat ablation outcome
A second ablation was performed in 65 patients (60%) a
median of 2.9 months (interquartile range: 2.3–4.5 months) after
the index procedure. Eight patients (7%) underwent the second
ablation 41 year after the index ablation because of very late
recurrence. The recurrent arrhythmia observed in these patients
was AT in 31 patients (48%), AT and AF in 12 patients (18%), and
AF in the remaining 22 patients (34%). In the 34 patients who
presented with AF after the index procedure, conduction recovery
was demonstrated in a median of 2 PVs during the repeat
ablation. Of the 34 patients, 6 patients (18%) did not show
conduction recovery in any PVs. In all patients with AF recurrence
after the index procedure, electrogram-based ablation was per-
formed because re-isolation of the PVs failed to terminate AF.
Of the 65 patients, 17 patients underwent a third ablation. The
recurrent arrhythmia was AT in 8 patients, AT and AF in 4 patients,
and AF in 5 patients. Of the 9 patients who presented with AF
after the second ablation, 6 patients did not have conduction
recovery in any PVs during the third ablation. In the remaining3 patients, conduction recovery was found in a single PV.
Electrogram-based ablation was performed in all patients with
AF recurrence. Additionally, 3 patients underwent a fourth abla-
tion (2 for AT, and 1 for AF, respectively). No complication
occurred in any of the repeat ablations.
The median follow-up period from the last ablation was
1.5 years (interquartile range: 0.8–2.7 years). The total number
of ablations performed was similar across the 3 groups (HF and
LVEFr45%: 1.970.2; HF and LVEF445%: 1.870.2; no HF:
1.870.1; p¼0.8). From the Kaplan–Meier curve, the arrhyth-
mia-free rate at 1-year follow-up was 67% in patients with HF and
LVEFr45%, 86% in patients with HF and LVEF445%, and 91%
in patients with no HF (log rank test: p¼0.0009; Fig. 4). The
arrhythmia-free rate in patients without HF declined slightly to
87% at 2-year follow-up, but did not change in the other 2 groups
(LVEF, r45% and 445%). After adjustment for age, gender, and
duration of continuous AF, HF and LVEFr45% group was asso-
ciated with a 6- to 7-fold increased risk of tachyarrhythmia
recurrence (Table 3).
Table 3
Multivariate analyses for recurrence of atrial tachyarrhythmias.
Hazard ratio (95% CI) p value
Age 0.98 (0.93–1.03) 0.5
Male 0.37 (0.12–1.26) 0.11
Duration of continuous AF (months) 0.95 (0.8–1.11) 0.5
HF and LVEFr45%
vs. HF and LVEF445% 6.05 (1.25–44.2) 0.025
vs. no HF 7.03 (2.23–21.1) 0.0015
Fig. 5. Changes in left ventricular ejection fraction (LVEF). LVEF at baseline and at
the 1-year follow-up are shown in patients with heart failure (HF) and LVEFr45%,
those with HF and LVEF445%, and those without HF (A). LVEF at baseline and
the end of the follow-up period are shown in patients with tachyarrhythmia
recurrence and those free from recurrence (no recurrence) for patients with HF
and LVEFr45% at baseline (B). p¼0.13 for comparison of the increase in LVEF
(LVEF at the end of follow-up minus baseline) between the 2 groups. Whiskers
represent standard error of the mean.
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had recurrent tachyarrhythmias. The recurrent tachyarrhythmia was
paroxysmal AF or AT in 15 of the 19 patients (79%), and persistent AT
in the remaining 4 patients. No patient had persistent AF. All 15
patients who had a paroxysmal form of recurrent tachyarrhythmia
had less than one symptomatic episode per month. Of the 89
patients free from tachyarrhythmias, 83 patients (93%) were not
taking antiarrhythmic drugs.3.3. Left ventricular function after the ablation
In all 3 groups, LVEF increased from baseline to the 1-year
follow-up (Fig. 5A). Patients with LVEFr45% showed the highest
increase in LVEF.
In patients with LVEFr45% at baseline, the increase in LVEF was
compared between the subgroups with and without tachyarrhyth-
mia recurrence (Fig. 5B). In all patients with tachyarrhythmia
recurrences, the clinical form of the recurrent tachyarrhythmia
was paroxysmal, and the frequency of tachyarrhythmia episode
was less than one per month. Over the follow-up period, LVEF
increased in both groups (tachyarrhythmia recurrence: 3877% to
60710%, p¼0.002; no recurrence: 3776% to 53710%, po0.0001).
The increase in LVEF in patients with and without recurrence was
2279% and 1675%, respectively (p¼0.13).4. Discussion
There is only limited data available on the outcomes after
catheter ablation for AF in HF patients. Our results may be helpful
in selecting patients for catheter ablation, determining ablation
strategy, and postprocedural management. The major ﬁnding of
this study was that LVEFr45% at the time of ablation was
associated with low arrhythmia-free rate after multiple ablations,
but having history of HF was not. Furthermore, during index
ablation, patients with LVEFr45% had shorter AF cycle length
and lower rate of AF termination than those in patients with
LVEF445%. These ﬁndings may suggest that the ﬁbrillatory
process was more advanced in patients with reduced LVEF.
A stepwise ablation strategy was used in the present study. In
this ablation strategy, electrogram-based ablation or linear abla-
tion was performed in combination with PV isolation, and the
desired procedural endpoint was termination of AF [15,16]. All
atrial regions except the sinus node and atrioventricular node are
candidates for ablation. Stepwise ablation is, therefore, consid-
ered to be optimal for patients with persistent AF, because AF
substrates are ubiquitously distributed in the atria and PVs
in these patients. In fact, the efﬁcacy of stepwise ablation for
patients without HF was 91% at the 1-year follow-up in this study,
which is comparable to rates for paroxysmal AF. However,
patients with reduced LVEF showed worse clinical outcome even
after undergoing stepwise ablation strategy. This is consistent
with previous reports in which different ablation strategies were
used [8,9]. It remains possible that more extensive ablation with a
high rate of AF termination may result in improved clinical
outcomes for patients with LV dysfunction. Further studies are
required to address this issue.
The arrhythmia-free rate was 67%–91% at 1-year after multiple
ablations depending on HF and LVEF status, although repeat
ablations were required for more than half of the patients. One
of the mechanisms responsible for tachyarrhythmia recurrences
was conduction recovery in the PVs or linear lesions. Elimination
of the dormant conduction unmasked by administration of ATP
can reduce conduction recovery between the PVs and LA [19–21],
but even with this approach, conduction recovery in the PVs was
still observed. Prevention of conduction recovery in linear lesions
is more challenging. Delivery of greater RF power may reduce
conduction recovery, but there are risks of complications such as
PV stenosis, steam pop, atrioesophageal ﬁstula, and pericarditis.
Thus, development of new ablation technologies is necessary for
both safety and efﬁcacy issues. However, prevention of conduc-
tion recovery in the PVs may not be the sole solution
for improvement of efﬁcacy. Our study group included some
patients who had AF recurrences that did not show conduction
recovery in any PV during repeat ablation. This fact clearly
indicates incremental efﬁcacy of ablation targeting the atrial
tissue in persistent AF.
As reported previously [4,5], this study showed that elimina-
tion of AF improved LVEF signiﬁcantly. In addition, patients with
tachyarrhythmia recurrence also had a signiﬁcant increase in LVEF
after the ablation. This may highlight the beneﬁt of catheter ablation
for AF in HF patients. We note that all tachyarrhythmia recurrences
consisted of occasional paroxysmal episodes (o1/month), suggest-
ing that infrequent episodes of tachyarrhythmias are unlikely to
reduce LV function.
In clinical practice, the form of AF presentation in HF patients
is often persistent, presumably because paroxysmal AF is likely to
rapidly progress to the persistent form in these patients [2]. Thus,
we focused on persistent rather than paroxysmal AF in this study.
We also chose to exclude long-standing persistent AF. Because the
duration of continuous AF is a predictor of a clinical outcome after
ablation for persistent AF [16], association of LV function with
Y. Takahashi et al. / Journal of Arrhythmia 28 (2012) 347–352352clinical outcome would likely be obscured if patients with long-
standing persistent AF were included.
4.1. Clinical implication
This study suggests that AF ablation targeting the atrial
substrate, in combination with PV isolation, can be a therapeutic
option for patients with LV dysfunction even after appropriate
rate control. Furthermore, catheter ablation at earlier stages may
be more favorable for HF patients, because ﬁbrillatory substrate
progresses rapidly in this cohort.
4.2. Limitations
Antiarrhythmic drugs were administered to patients without
HF for a short-term after the ablation, but not to patients with
reduced LVEF. This may contribute to the high arrhythmia-free
rate in patients without HF. It has been reported that in patients
with normal LV function, short-term antiarrhythmic drug therapy
failed to improve mid-term clinical outcome after ablation [22].
However, it is unknown whether this result also applies to HF
patients.
To exclude the effects of a potential link between AF and
structural heart disease, patients with ischemic heart disease,
valvular disease, or hypertrophic cardiomyopathy were not
included in the present study.
The complication rate in patients with HF or reduced LVEF
seemed modest, but a greater number of patients are required to
assess the incidence of infrequent events. Finally, we did not
study the efﬁcacy and safety of AF ablation in HF patients in the
NYHA functional class III or IV.5. Conclusion
In our study, only two-thirds of HF patients with LVEFr45%
remained free of arrhythmia after ablation for persistent AF, unlike
the much higher success rates for patients with LVEF445%. Never-
theless, in these LVEFr45% patients, LVEF improved in both arrhyth-
mia-free and non-arrhythmia patients, reﬂecting the reduction in the
AF burden and highlighting the beneﬁts of stepwise ablation for
persistent AF in HF patients.Conﬂict of interest
None.
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